Content area
Full Text
Helicos BioSciences, founded in 2003, focuses on innovative genetic analysis technologies for the research, drug discovery and development, and diagnostic markets. Helicos'' proprietary True Single Molecule Sequencing (tSMS)TM technology allows the simultaneous, direct sequencing of billions of DNA strands, enabling scientists to perform experiments and ask questions never before possible. Helicos, a recipient of the US$1000 genome grant, is committed to providing scientists the tools to unlock the era of genomic medicine.
Helicos is led by a veteran life sciences executive team, including Chairman and CEO, Stanley Lapidus, and President and Chief Operating Officer (COO), Steve Lombardi. The Scientific Advisory Board, chaired by founder Stephen Quake, comprises a world-class scientific research board. Helicos has brought together some of the country''s most renowned genomic experts, including Leroy Hood, Jeffrey Trent and Victor Velculescu to offer guidance and expertise as the company moves toward commercialization of a new category of genetic analysis technology.
The company''s premier product, the Helicos(TM)(TM) Genetic Analysis Platform, is the world''s first DNA Microscope. The platform includes the HeliScope(TM)(TM) Single Molecule Sequencer, the HeliScope Analysis Engine for near real-time image analysis, the HeliScope Sample Loader, proprietary flow cells and single molecule grade assay reagents. Based on Helicos'' tSMS technology, the Helicos Genetic Analysis Platform enables ultra-high-throughput genetic analysis by directly tracking the synthesis of single molecules of nucleic acids and deciphering their sequence. Unlike current methods of sequencing DNA, Helicos'' tSMS sequencing-by-synthesis approach does not require DNA amplification. This advance greatly simplifies sample preparation, exponentially increases throughput, dramatically lowers the cost of individual analyses and enables single-molecule data resolution.
The Helicos Genetic Analysis Platform represents the first comprehensive and universal solution for single molecule genetic analysis and will have extensive capabilities in basic and translational research and pharmaceutical R&D, which will increase the potential for improved drug therapies, personalized medicine and more accurate molecular diagnostics for diseases, such as cancer.
Future perspective
Currently, the US healthcare expenditure approaches US$2 trillion annually, with expected growth to exceed US$4 trillion within the next 10 years. The debate regarding the need to reduce costs, provide access to all individuals and improve the current healthcare system becomes ever more pressing. Regardless of the outcome of this debate, one thing is clear -- our increasing knowledge...